Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsGlobeNewsWire • 08/13/24
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 08/02/24
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald RigorGlobeNewsWire • 07/29/24
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology PlatformGlobeNewsWire • 07/18/24
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory BoardGlobeNewsWire • 07/16/24
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of DirectorsBusiness Wire • 06/27/24
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13Business Wire • 06/11/24
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsBusiness Wire • 06/10/24
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingBusiness Wire • 06/03/24
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsBusiness Wire • 05/31/24
Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TVAccesswire • 05/17/24
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsBusiness Wire • 05/14/24
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingBusiness Wire • 05/01/24
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24Business Wire • 04/23/24
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingBusiness Wire • 04/19/24
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingBusiness Wire • 04/16/24
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024Business Wire • 04/09/24
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsBusiness Wire • 03/15/24
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerBusiness Wire • 03/11/24
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceBusiness Wire • 02/12/24
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardBusiness Wire • 01/08/24
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy SummitBusiness Wire • 12/13/23
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsBusiness Wire • 11/14/23